We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

63 hedge funds and large institutions have $81.6M invested in Aevi Genomic Medicine Inc in 2015 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 28 increasing their positions, 9 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 2

211% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 9

49% more capital invested

Capital invested by funds: $54.9M → $81.6M (+$26.7M)

24% more funds holding

Funds holding: 51 → 63 (+12)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
63
Holders Change
+12
Holders Change %
+23.53%
% of All Funds
1.65%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
28
Reduced
9
Closed
2
Calls
$284K
Puts
–
Net Calls
+$284K
Net Calls Change
-$29K

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$10.2M
2
Jennison Associates
Jennison Associates
New York
+$6.15M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$6.11M
4
BBA
Baker Bros. Advisors
New York
+$5.19M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$5.19M

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$614K
2
BGA
Belmont Global Advisors
Texas
-$611K
3
Morgan Stanley
Morgan Stanley
New York
-$43K
4
PVH
Psagot Value Holdings
Israel
-$14.9K
5
BA
BlackRock Advisors
Delaware
-$11.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
BC
1
Broadfin Capital
New York
$18.3M +$10.2M +1,500,000 +97%
Jennison Associates
2
Jennison Associates
New York
$10.5M +$6.15M +906,153 +108%
OM
3
Opaleye Management
Massachusetts
$8.37M +$2.25M +331,600 +31%
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$5.42M +$6.11M +900,000 New
QF
5
QVT Financial
New York
$5.22M +$4.07M +600,000 +224%
BBA
6
Baker Bros. Advisors
New York
$4.61M +$5.19M +765,000 New
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$4.61M +$5.19M +765,000 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$4.59M +$1.02M +150,227 +25%
BFA
9
BlackRock Fund Advisors
California
$3.59M +$1.07M +157,767 +36%
BIT
10
BlackRock Institutional Trust
California
$3.56M +$575K +84,638 +17%
Baillie Gifford & Co
11
Baillie Gifford & Co
United Kingdom
$2.17M – – –
Northern Trust
12
Northern Trust
Illinois
$1.39M +$351K +51,725 +29%
State Street
13
State Street
Massachusetts
$1.34M +$397K +58,465 +36%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$1.09M +$255K +37,631 +26%
BCM
15
Bridgeway Capital Management
Texas
$716K – – –
LPL Financial
16
LPL Financial
California
$538K +$293K +43,211 +92%
TCIM
17
TIAA CREF Investment Management
New York
$502K +$208K +30,700 +58%
SIM
18
Spark Investment Management
New York
$465K +$526K +77,400 New
Bank of New York Mellon
19
Bank of New York Mellon
New York
$464K +$65.9K +9,700 +14%
BIM
20
BlackRock Investment Management
Delaware
$411K +$64.2K +9,459 +16%
BGA
21
Belmont Global Advisors
Texas
$391K -$611K -90,000 -58%
California Public Employees Retirement System
22
California Public Employees Retirement System
California
$307K +$346K +51,000 New
AA
23
ALPS Advisors
Colorado
$261K +$294K +43,290 New
California State Teachers Retirement System (CalSTRS)
24
California State Teachers Retirement System (CalSTRS)
California
$247K +$71.1K +10,466 +34%
TD Asset Management
25
TD Asset Management
Ontario, Canada
$220K +$248K +36,500 New
1
2 3

GNMX Hedge Fund Activity: Q4 2015 in Review

63 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q4 2015, worth a combined $81.6M — up 49% from $54.9M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new GNMX positions and 2 closed out — a net gain of 12 holders — while 28 added to existing stakes and 9 trimmed.

The largest buyer was Broadfin Capital, adding an estimated $10.2M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $614K sold.

  • 63 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q4 2015, up from 51 in Q3 2015.
  • Funds reported $81.6M of Aevi Genomic Medicine Inc stock for Q4 2015, up 49% quarter-over-quarter.
  • 14 funds opened new Aevi Genomic Medicine Inc positions in Q4 2015 and 2 closed out, a net change of +12 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q4 2015 was Broadfin Capital, an estimated $10.2M added.
  • The largest Aevi Genomic Medicine Inc seller in Q4 2015 was Alyeska Investment Group, an estimated $614K sold.

Based on aggregated 13F filings for Q4 2015.